INKON Life Technology Co Ltd (300143) - Total Assets
Based on the latest financial reports, INKON Life Technology Co Ltd (300143) holds total assets worth CN¥4.17 Billion CNY (≈ $610.67 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 300143 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
INKON Life Technology Co Ltd - Total Assets Trend (2007–2025)
This chart illustrates how INKON Life Technology Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore INKON Life Technology Co Ltd (300143) investment intensity to see how much of total assets are deployed in long-term investments.
INKON Life Technology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
INKON Life Technology Co Ltd's total assets of CN¥4.17 Billion consist of 43.6% current assets and 56.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 25.5% |
| Accounts Receivable | CN¥297.97 Million | 7.1% |
| Inventory | CN¥87.16 Million | 2.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥216.59 Million | 5.2% |
| Goodwill | CN¥1.01 Billion | 24.1% |
Asset Composition Trend (2007–2025)
This chart illustrates how INKON Life Technology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300143 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: INKON Life Technology Co Ltd's current assets represent 43.6% of total assets in 2025, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 25.5% of total assets in 2025, up from 1.8% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 4.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 24.1% of total assets.
INKON Life Technology Co Ltd Competitors by Total Assets
Key competitors of INKON Life Technology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
INKON Life Technology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 2.57 | 5.35 |
| Quick Ratio | 2.10 | 2.46 | 5.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.00 Billion | CN¥1.10 Billion | CN¥817.80 Million |
INKON Life Technology Co Ltd - Advanced Valuation Insights
This section examines the relationship between INKON Life Technology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.35 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 18.5% |
| Total Assets | CN¥4.19 Billion |
| Market Capitalization | $761.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values INKON Life Technology Co Ltd's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: INKON Life Technology Co Ltd's assets grew by 18.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for INKON Life Technology Co Ltd (2007–2025)
The table below shows the annual total assets of INKON Life Technology Co Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.19 Billion ≈ $613.51 Million |
+18.54% |
| 2024-12-31 | CN¥3.54 Billion ≈ $517.54 Million |
+47.35% |
| 2023-12-31 | CN¥2.40 Billion ≈ $351.23 Million |
+18.36% |
| 2022-12-31 | CN¥2.03 Billion ≈ $296.74 Million |
-18.00% |
| 2021-12-31 | CN¥2.47 Billion ≈ $361.89 Million |
-6.70% |
| 2020-12-31 | CN¥2.65 Billion ≈ $387.89 Million |
+35.44% |
| 2019-12-31 | CN¥1.96 Billion ≈ $286.39 Million |
-25.37% |
| 2018-12-31 | CN¥2.62 Billion ≈ $383.74 Million |
+0.43% |
| 2017-12-31 | CN¥2.61 Billion ≈ $382.08 Million |
+3.04% |
| 2016-12-31 | CN¥2.53 Billion ≈ $370.79 Million |
+37.05% |
| 2015-12-31 | CN¥1.85 Billion ≈ $270.55 Million |
+129.96% |
| 2014-12-31 | CN¥804.00 Million ≈ $117.65 Million |
-22.27% |
| 2013-12-31 | CN¥1.03 Billion ≈ $151.35 Million |
+3.44% |
| 2012-12-31 | CN¥999.85 Million ≈ $146.31 Million |
+20.43% |
| 2011-12-31 | CN¥830.26 Million ≈ $121.49 Million |
-2.47% |
| 2010-12-31 | CN¥851.32 Million ≈ $124.57 Million |
+278.97% |
| 2009-12-31 | CN¥224.64 Million ≈ $32.87 Million |
+36.75% |
| 2008-12-31 | CN¥164.27 Million ≈ $24.04 Million |
+17.14% |
| 2007-12-31 | CN¥140.23 Million ≈ $20.52 Million |
-- |
About INKON Life Technology Co Ltd
INKON Life Technology Co., Ltd. focuses on building an ecosystem platform for providing medical services for tumors in China and internationally. It provides medical devices solutions for radiotherapy, life support, image enhancement, and chronic disease treatment; and oncology medical services, as well as equipment for cancer prevention, diagnosis, treatment, and rehabilitation. The company was … Read more